Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on February 26, 2026. The report covers the month of February 2026 and details the execution of a share buyback program pursuant to a non-discretionary agreement with BNP Paribas SA (the "Broker").
Key Financial Metrics and Transaction Details
The filing provides specific data regarding the repurchase of ordinary shares of 31½ pence each:
- Shares Purchased: 545,000 ordinary shares.
- Price Range: Lowest price paid was 2,155.00p; highest price paid was 2,211.00p.
- Average Price: Volume-weighted average price paid was 2,186.88p.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON (London Stock Exchange).
- Treasury Holdings: Following this purchase, the Company holds 243,597,094 ordinary shares in treasury.
- Shares in Issue: 4,072,555,332 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.98% of the total voting rights.
Material Changes and Program Progress
This transaction is part of the Company's existing buyback programme. Since the agreement was announced on February 17, 2026, the Company has purchased a total of 3,706,000 ordinary shares. The filing confirms that the purchased shares are held as Treasury shares and do not carry voting rights.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties described in GSK's Annual Report on Form 20-F for 2024 and Q4 Results for 2025.
Key Facts for Investor Verification
- Verify the total number of shares purchased since February 17, 2026 (3,706,000) against the Company's total buyback authorization limits.
- Confirm the updated percentage of voting rights held in treasury (5.98%) to assess potential dilution or concentration of voting power among remaining shareholders.
- Review the volume-weighted average price (2,186.88p) relative to the market price at the time of execution to evaluate the efficiency of the buyback.
- Monitor the remaining capacity of the buyback programme to determine future capital allocation plans.